We speculate that patients with elevated baseline TSH level may inherently have low levels of thyroid autoimmunity and are therefore more likely to develop thyroid dysfunction after anti-PD-1 therapy. This evidence concerns the gene PDCD1 and autoimmune thyroid disease.